Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.

Macconell L, Pencek R, Li Y, Maggs D, Porter L.

Diabetes Metab Syndr Obes. 2013;6:31-41. doi: 10.2147/DMSO.S35801. Epub 2013 Jan 21.

2.

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes.

Ridge T, Moretto T, MacConell L, Pencek R, Han J, Schulteis C, Porter L.

Diabetes Obes Metab. 2012 Dec;14(12):1097-103. doi: 10.1111/j.1463-1326.2012.01639.x. Epub 2012 Jul 19.

3.

Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.

Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J.

Postgrad Med. 2013 May;125(3):47-57. doi: 10.3810/pgm.2013.05.2660.

PMID:
23748506
4.

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, Trautmann M, Porter L.

J Clin Endocrinol Metab. 2011 May;96(5):1301-10. doi: 10.1210/jc.2010-2081. Epub 2011 Feb 9.

PMID:
21307137
5.

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.

Wysham CH, MacConell LA, Maggs DG, Zhou M, Griffin PS, Trautmann ME.

Mayo Clin Proc. 2015 Mar;90(3):356-65. doi: 10.1016/j.mayocp.2015.01.008.

PMID:
25744115
6.

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.

Clin Ther. 2012 Oct;34(10):2082-90. doi: 10.1016/j.clinthera.2012.09.007. Epub 2012 Sep 29.

PMID:
23031623
7.

Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.

Aroda VR, DeYoung MB.

Postgrad Med. 2011 Sep;123(5):228-38. doi: 10.3810/pgm.2011.09.2479. Review.

PMID:
21904106
8.

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

Taylor K, Gurney K, Han J, Pencek R, Walsh B, Trautmann M.

BMC Endocr Disord. 2011 Apr 29;11:9. doi: 10.1186/1472-6823-11-9.

9.
10.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
12.

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.

Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, Taylor K.

Diabet Med. 2011 Jun;28(6):705-14. doi: 10.1111/j.1464-5491.2011.03301.x.

13.

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.

Bergenstal RM, Li Y, Porter TK, Weaver C, Han J.

Diabetes Obes Metab. 2013 Mar;15(3):264-71. doi: 10.1111/dom.12026. Epub 2012 Nov 12.

15.

Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.

Iványi T, Fövényi J, Faludi P, Han J, Macconell L, Wille S, Kiljanski J.

Clin Ther. 2012 Jun;34(6):1301-13. doi: 10.1016/j.clinthera.2012.04.022. Epub 2012 May 16.

PMID:
22608106
16.

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G.

Lancet. 2013 Jan 12;381(9861):117-24. doi: 10.1016/S0140-6736(12)61267-7. Epub 2012 Nov 7.

PMID:
23141817
17.

Exenatide once-weekly clinical development: safety and efficacy across a range of background therapies.

Stonehouse A, Walsh B, Cuddihy R.

Diabetes Technol Ther. 2011 Oct;13(10):1063-9. doi: 10.1089/dia.2011.0076. Epub 2011 Jul 6. Review.

18.

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.

Curr Med Res Opin. 2008 Jan;24(1):275-86.

PMID:
18053320
20.

Exenatide extended-release; clinical trials, patient preference, and economic considerations.

Doggrell SA.

Patient Prefer Adherence. 2013;7:35-45. doi: 10.2147/PPA.S30627. Epub 2013 Jan 9.

Supplemental Content

Support Center